Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

Lishomwa C. Ndhlovu; Tracie Umaki; Glen M. Chew; Dominic C. Chow; Melissa Agsalda; Kalpana J. Kallianpur; Robert Paul; Guangxiang Zhang; Erika Ho; Nancy Hanks; Beau Nakamoto; Bruce T. Shiramizu; Cecilia M. Shikuma

doi:10.1007/s13365-014-0279-x

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

Lishomwa C. Ndhlovu, Tracie Umaki, Glen M. Chew, Dominic C. Chow, Melissa Agsalda, Kalpana J. Kallianpur, Robert Paul, Guangxiang Zhang, Erika Ho, Nancy Hanks, Beau Nakamoto, Bruce T. Shiramizu, Cecilia M. Shikuma

University of Missouri-St. Louis

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of NeuroVirology
Volume	20
DOIs	https://doi.org/10.1007/s13365-014-0279-x
State	Published - Dec 1 2014

Disciplines

Virology
Medicine and Health Sciences
Immunology and Infectious Disease

Access to Document

10.1007/s13365-014-0279-xLicense: Unspecified

Cite this

Ndhlovu, L. C., Umaki, T., Chew, G. M., Chow, D. C., Agsalda, M., Kallianpur, K. J., Paul, R., Zhang, G., Ho, E., Hanks, N., Nakamoto, B., Shiramizu, B. T., & Shikuma, C. M. (2014). Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). Journal of NeuroVirology, 20. https://doi.org/10.1007/s13365-014-0279-x

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). / Ndhlovu, Lishomwa C.; Umaki, Tracie; Chew, Glen M. et al.
In: Journal of NeuroVirology, Vol. 20, 01.12.2014.

Research output: Contribution to journal › Article › peer-review

Ndhlovu, LC, Umaki, T, Chew, GM, Chow, DC, Agsalda, M, Kallianpur, KJ, Paul, R , Zhang, G, Ho, E, Hanks, N, Nakamoto, B, Shiramizu, BT & Shikuma, CM 2014, 'Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).', Journal of NeuroVirology, vol. 20. https://doi.org/10.1007/s13365-014-0279-x

Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). Journal of NeuroVirology. 2014 Dec 1;20. doi: 10.1007/s13365-014-0279-x

Ndhlovu, Lishomwa C. ; Umaki, Tracie ; Chew, Glen M. et al. / Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). In: Journal of NeuroVirology. 2014 ; Vol. 20.

@article{0f31e366e8084a6fa349e25bc42fc184,

title = "Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).",

author = "Ndhlovu, {Lishomwa C.} and Tracie Umaki and Chew, {Glen M.} and Chow, {Dominic C.} and Melissa Agsalda and Kallianpur, {Kalpana J.} and Robert Paul and Guangxiang Zhang and Erika Ho and Nancy Hanks and Beau Nakamoto and Shiramizu, {Bruce T.} and Shikuma, {Cecilia M.}",

note = "Lishomwa C. Ndhlovu Tracie Umaki Glen M. Chew Dominic C. Chow Melissa Agsalda Kalpana J. Kallianpur Robert Paul Guangxiang Zhang Erika Ho Nancy Hanks Beau Nakamoto Bruce T. Shiramizu Cecilia M. Shikuma HIV-associated neurocognitive disorders (HAND) continues to be prevalent (30-50 %) despite plasma HIV-RNA suppression with combination antiretroviral therapy (cART).",

year = "2014",

month = dec,

day = "1",

doi = "10.1007/s13365-014-0279-x",

language = "American English",

volume = "20",

journal = "Journal of NeuroVirology",

}

TY - JOUR

T1 - Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

AU - Ndhlovu, Lishomwa C.

AU - Umaki, Tracie

AU - Chew, Glen M.

AU - Chow, Dominic C.

AU - Agsalda, Melissa

AU - Kallianpur, Kalpana J.

AU - Paul, Robert

AU - Zhang, Guangxiang

AU - Ho, Erika

AU - Hanks, Nancy

AU - Nakamoto, Beau

AU - Shiramizu, Bruce T.

AU - Shikuma, Cecilia M.

N1 - Lishomwa C. Ndhlovu Tracie Umaki Glen M. Chew Dominic C. Chow Melissa Agsalda Kalpana J. Kallianpur Robert Paul Guangxiang Zhang Erika Ho Nancy Hanks Beau Nakamoto Bruce T. Shiramizu Cecilia M. Shikuma HIV-associated neurocognitive disorders (HAND) continues to be prevalent (30-50 %) despite plasma HIV-RNA suppression with combination antiretroviral therapy (cART).

PY - 2014/12/1

Y1 - 2014/12/1

UR - https://rd.springer.com/content/pdf/10.1007%2Fs13365-014-0279-x.pdf

U2 - 10.1007/s13365-014-0279-x

DO - 10.1007/s13365-014-0279-x

M3 - Article

VL - 20

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

ER -

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

Disciplines

Access to Document

Other files and links

Cite this